Skip to content

Improving Keloids Using Targeted Ultraviolet-B Irradiation

Improving Keloids Using Targeted Ultraviolet-B Irradiation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03160053
Enrollment
2
Registered
2017-05-19
Start date
2015-06-23
Completion date
2018-06-15
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keloid

Brief summary

Treatment of keloids with targeted Ultraviolet-Beta (UVB) radiation will improve the clinical appearance and induration of lesions.

Interventions

DEVICENB-UVB

NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Each participant served as his/hers own control.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants must be 18 years old or over * Participants must have a diagnosis of keloid * No treatment with topical or intralesional steroids for 1 month prior to study

Exclusion criteria

* Patients who are unable to provide informed consent * A history of photosensitivity, lupus erythematosus, porphyria or current use of a known photosensitizing drug * Unwillingness to stop with topical or intralesional steroids for 1 month prior to study * A history of malignant melanoma * A history of radiation therapy to area of interest * Subjects who self-report that they are pregnant or nursing

Design outcomes

Primary

MeasureTime frameDescription
Clinical Appearance As Assessed by the Patient and Observer Scar Assessment (POSAS) Scale16 weeksInvestigators will evaluate the pre- and post-study clinical photographs of all participants. The grading investigator will grade the degree of improvement using the POSAS scale to measure the clinical appearance of the keloids

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026